321 completed, 98 unknown, 46 recruiting, 46 terminated. 552 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 552 | Completed 321, Unknown 98, Recruiting 46, Terminated 46, Withdrawn 17, Not yet recruiting 14, Active not recruiting 9, Enrolling by invitation 1 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Switch in Bloodstream Infections in Immunocompromised Children Oral antibiotic therapy, Standard IV antibiotic therapy - Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter | Phase 4 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 114 | 2026-11-09 | 2026-11-10 |
| VATS or Intrapleural Enzymatic Therapy for Patients With Empyema. VATS group, IET - Empyema, Pleural, Pleural Infections | Phase 4 | Recruiting | Amsterdam UMC | 164 | 2026-11-07 | 2026-11-10 |
| Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock Angiotensin II, Norepinephrine - Septic Shock | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 78 | 2026-11-01 | 2026-09-24 |
| Brain and Blood Vessel Health Following Endometriosis Treatment in People With Endometriosis Investigate how norethindrone acetate, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health, Investigate how Orlissa, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health, Investigate how Oriahnn, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health - Endometriosis, Endometriosis and Dysmenorrhea | Phase 4 | Not yet recruiting | Colorado State University | 45 | 2026-10-01 | 2026-09-02 |
| Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine N-Acetylcysteine (NAC) Treatment - Sepsis, Acute Infection | Phase 4 | Recruiting | Theis S. Itenov | 360 | 2026-09-07 | 2026-09-16 |
| Oral Switch in Pediatric Bloodstream Infections Oral antibiotic therapy, Standard IV antibiotic therapy - Bloodstream Infection, Bacteremia Sepsis | Phase 4 | Recruiting | Ulrikka Nygaard | 150 | 2026-09-01 | 2026-10-19 |
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial Caspofungin only within the study, Caspofungin for 3 days within the study, Placebo only within the study - Candidemia, Invasive Candidiasis | Phase 4 | Not yet recruiting | Oliver Cornely, MD | 420 | 2026-09-01 | 2026-09-01 |
| A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients Extended infusion time of the following beta-lactam: meropenem, Short-term infusion time of the following beta-lactam: meropenem, Extended infusion time of the following beta-lactam: piperacillin/tazobactam - Infection, Sepsis | Phase 4 | Recruiting | Semmelweis University | 110 | 2026-09-01 | 2026-11-06 |
| Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course' Antibiotics for duration of symptoms, Antibiotics for duration of prescribed course - Urinary Tract Infection, Cellulitis | Phase 4 | Recruiting | Murdoch Childrens Research Institute | 200 | 2026-08-18 | 2026-08-21 |
| The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) Piperacillin + Tazobactam, meropenem - Infection, Acute Kidney Injury | Phase 4 | Recruiting | Bassett Healthcare | 852 | 2026-08-17 | 2026-10-15 |
| Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression - Sepsis and Septic Shock, Acute Respiratory Failure | Phase 4 | Recruiting | University Hospital, Strasbourg, France | 212 | 2026-08-11 | 2026-08-20 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| PROMab Trial: Ampicillin With or Without Gentamicin for Term Prelabour Rupture of Membranes Ampicillin, Ampicillin + gentamicin - Rupture of Membranes Prior to Onset of Labor | Phase 4 | Not yet recruiting | Sarawak General Hospital | 320 | 2026-07-01 | 2026-05-04 |
| Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury Citrate anticoagulation, Nafamostat Mesylate - Sepsis, Acute Kidney Injury | Phase 4 | Not yet recruiting | Jianfeng Xie | 1162 | 2026-06-10 | 2026-06-03 |
| Anemia Therapy in Patients With Infective Endocarditis Adjunctive anemia therapy - Infective Endocarditis (IE), Severe Anemia | Phase 4 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 74 | 2026-05-15 | 2026-05-29 |
| Aminoglycosides in Early Sepsis Gentamicin + narrow spectrum betalactam, Cefotaxime, Piperacillin-tazobactam - Sepsis | Phase 4 | Recruiting | University Hospital, Akershus | 1900 | 2026-04-23 | 2026-10-28 |
| Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Hyperbaric oxygen treatment, Standard of Care (Investigator Choice) - Necrotizing Soft Tissue Infection | Phase 4 | Recruiting | Ole Hyldegaard | 1480 | 2026-04-04 | 2026-09-04 |
| Flush, Lyse, Operate Intrapleural Saline with possible escalation to intraplerual alteplase and dornase. - Complicated Parapneumonic Effusion, Empyema, Pleural | Phase 4 | Not yet recruiting | Dartmouth-Hitchcock Medical Center | 30 | 2026-04-01 | 2026-05-18 |
| Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis Nicotinamide 1000 mg - Sepsis - to Reduce Mortality in the Intensive Care Unit | Phase 4 | Completed | Ain Shams University | 60 | 2026-03-28 | 2026-10-20 |
| Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock Hydrocortisone plus Fludrocortisone, Standard care - Septic Shock | Phase 4 | Recruiting | Northern Jiangsu People's Hospital | 336 | 2026-03-02 | 2026-03-04 |
Showing 20 of 552. Sign in to see all of them.
Sepsis (144) · Shock, Septic (81) · Bacteremia (35) · Cellulitis (22) · Atherosclerosis (21) · Infections (20) · Systemic Inflammatory Response Syndrome (18) · Diabetes Mellitus, Type 2 (17) · Insulin Resistance (16) · Neonatal Sepsis (16) · Coronary Artery Disease (15) · Pain (15) · Abscess (14) · Cardiovascular Diseases (10)
Pathologic Processes (552) · Pathological Conditions, Signs and Symptoms (552) · Infections (286) · Systemic Inflammatory Response Syndrome (245) · Sepsis (101) · Shock (97) · Cardiovascular Diseases (78) · Bacterial Infections and Mycoses (65) · Vascular Diseases (62) · Signs and Symptoms (59) · Urogenital Diseases (55) · Nutritional and Metabolic Diseases (53) · Bacterial Infections (48) · Respiratory Tract Diseases (48)
Sodium Chloride (22) · Saline Solution (18) · Meropenem (12) · Atorvastatin (11) · Daptomycin (11) · Norepinephrine (11) · Piperacillin, Tazobactam Drug Combination (11) · Dexmedetomidine (10) · Hydrocortisone (10) · Ascorbic Acid (8) · Midazolam (8) · Albumins (7) · Celecoxib (7) · Dexamethasone (7) · Gentamicins (7)
Southeast University, China (8) · Ain Shams University (7) · Emory University (6) · Medical University of Vienna (6) · Pfizer (6) · Eli Lilly and Company (5) · Radboud University Medical Center (5) · Copenhagen University Hospital, Rigshospitalet (4) · Peking Union Medical College Hospital (4) · University of North Carolina, Chapel Hill (4) · Amgen (3) · Assistance Publique - Hôpitaux de Paris (3) · Assiut University (3) · Bausch & Lomb Incorporated (3) · Cairo University (3)
United States (138) · China (44) · Italy (27) · Brazil (24) · France (24) · Canada (22) · Denmark (19) · Netherlands (19) · Egypt (17) · Spain (17) · Germany (16) · Turkey (Türkiye) (14) · Switzerland (13) · Taiwan (13) · Australia (12)
Bernd Jilma, MD (3) · Alfonso M. M Cueto-Manzano, MD, MSc, PhD (2) · Amanda Wilkins, MBBS (2) · Andrea M Isidori, MD, PhD (2) · Angelo Avogaro, M.D. Ph.D. (2) · Binita Shah, MD (2) · Calvin Q Pan, MD (2) · Dr R Gopinath (2) · Erhei Dai, MD (2) · Gian Paolo Fadini, M.D. (2) · Joao P Teixeira, MD (2)
PMID 23963131, PMID 28459966, PMID 28597967, PMID 30394918, PMID 31280481, PMID 33891293, PMID 34605781, PMID 10321661, PMID 10697064, PMID 10923728, PMID 11409564, PMID 11529214, PMID 11555797, PMID 11574381, PMID 11588440, PMID 11771602, PMID 12186604, PMID 12487041, PMID 12500513, PMID 12519925, PMID 12710654, PMID 14638511, PMID 15187514, PMID 15229100, PMID 15341352, PMID 15343008, PMID 15585684, PMID 15774007, PMID 16113473, PMID 16134766, PMID 16155063, PMID 16254497, PMID 16632649, PMID 16641463, PMID 16757502, PMID 16879732, PMID 17353249, PMID 17355677, PMID 17394957, PMID 17403700, PMID 17403800, PMID 17538551, PMID 17556722, PMID 17761367, PMID 18090011, PMID 18096708, PMID 18156891, PMID 18211990, PMID 18270378, PMID 18305265
2023 (6), 2014 (4), 2015 (4), 2017 (3), 2025 (2), 2008 (1), 2016 (1), I01CX002358 (1), K23AT002862 (1), M01RR000827 (1), P30AI045008 (1), P30DK063491 (1), R01DK071277 (1), R01DK075877 (1), R01HD097578 (1)